Immunotherapy: Changing Patient Outcomes in SCLC

CME
30/06/2019

Listen "Immunotherapy: Changing Patient Outcomes in SCLC "

Descargar episodio Ver en sitio original

Episode Synopsis



Host: Leora Horn, MD, MSc



Please note: This activity is no longer available for continuing education credit. Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with a poor prognosis. The recent addition of immunotherapy to the treatment landscape has changed the standard of care for ES-SCLC. In this interactive activity an expert will guide you through the latest evidence on checkpoint inhibitors for the management of ES-SCLC and offer expert insight into effectively and safely incorporating immunotherapy into your practice to improve patient outcomes.

More episodes of the podcast CME

Updates in Major Depressive Disorder with Insomnia 07/11/2025
Women’s Sleep Health – Addressing Gaps in OSA Diagnosis and Treatment Across Life Stages 15/10/2025
Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis 03/10/2025
Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers 30/09/2025
Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers 30/09/2025
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers 30/09/2025
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer 30/09/2025
From Resistance to Response: Evolving Strategies in MDD Management 26/09/2025
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 26/09/2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025 26/09/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA